

Combating Corruption and Promoting Equity in the Health Sector

Lessons from the Field

Different systems, different risks, complementary strategies

Karen Hussmann

Independent expert and consultant

Member of Transparency International



Agenda of the session



- What is different in the health sector in terms of corruption and what are the main policy options to address the problem?
- What is a systems and actor perspective good for?
- Experience of Colombia in addressing corruption in the health sector
- Some lessons learned

What is different in the health sector ?

Special characteristics of the health sector

- ❖ **Market failures:** in particular **information asymmetry** → **new regulations & new risks**
- ❖ **Many actors** with (often) opaque relations and different (legitimate) interests
- ❖ **Blurred lines** between abuse, unethical behaviour and mistakes

Corruption manifests differently in different sectors

- **Amount of resources;**
 - How they are mobilized, assigned and spent;
 - Power structures of each sector → political economies and state administration
- **Types of corruption vary**
 - Individual bribes, schemes / pyramids of bribes;
 - Kick-back schemes;
 - Organized versus uncontrolled corruption;
 - Capture or cooptation of illegal actors.

What are policy options for addressing corruption in health?

▶ International initiatives :

- ▶ META – GGM

▶ Holistic sector policies / strategies

- ▶ Strong political will for service delivery vs. „smoke-screens“ (more formal than real)

▶ Focus on sub-systems:

- ▶ E.g. on pharama policy (GGM-WHO)

▶ Institutional level initiatives


- ▶ Hospitals, health centres, health regulators, central drug stores; local health departments

▶ „Punctual patches“ or „Opportunistic incremental“:

- ▶ Remedy specific problems (particular demands or scandals) -- Drug prices at hospitals; user fees; financial administr.
- ▶ Limited political will – focus on legitimizing power
- ▶ Civil society and donor supported iniatives

- Little evidence still on pros and cons of different approaches
- Ideally combine and take into account political feasibility and

What is a systems and actor perspective good for?



What can be learned from applying a system perspective?

Case studies on Colombia – Peru

Analysis of health systems directed at the poor (2011)

- ▶ Colombia: regulated competition (public-private)
- ▶ Peru: public provision

Key points

- ▶ Different systems – different risks
- ▶ Deficient control; lack of transparency and accountability
- ▶ Systems reforms can „reform“ the risks of corruption
- ▶ Corruption is ideology-free (public, private, left, right, etc.)
- ▶ Risks of law, regulatory and institutional capture get little attention

Importance to acknowledge the **responsibility of all actors** → **trust and legitimacy**

Resource generation

Deficient control
Lack of transparency

National Government

Evasion and elusion in RC
→ Fosyga
Tax evasion

Financing Beneficiary identification

Manipulation and fraud in beneficiary identification
Political pressures

Local Authorities

Fraudulent & "political" procurement
Negotiations for beneficiary affiliation
Political favours in staff of EPS-S
Transfers lower than budgeted
Delays in payments

Insurance contracting

Non-existent affiliated people
Over-billing and fraud in invoices
Fraudulent billing of non-POS-S services
Commissions to EPS-S

Health Insurers (EPS)

Clientelism in selection of IPS executives
Conflicts of interest in control ("inventorías")

Delays in payments

Provider contracting

Over-billing and fraud
Collusion for price-fixing

Health Providers (IPS)

Creation of artificial queues
Incomplete treatments and negation of services
Induction of unnecessary treatments outside of insurance benefit package

Service provision

Fraud in use of health insurance card

Patients


Procurement

**HR
Drugs / supplies
Equipments**

Armed actors

Potential capture of laws / institutions
Deficient control and oversight

Deficient control
Lack of transparency



Colombia experience post 2012



Combating corruption in the health sector in Colombia

Context:

2011 major scandal hits health system (financial and credibility crisis); systemic failure with responsibility of all actors → Recovering trust and legitimacy

Response of the state:

- Political-technical leadership in Ministry of Health and key national entities
- Institutional reforms and new leaderships
 - Superintendency; Invima (food and drug agency); IETS (conflicts of interest)
- Recognises transparency and access to information (fundamental right since 2014) as fundamental principle of State administration
- Funding flows
 - From national to sub-national levels (actors, processes, accountability)
 - Between providers and insurers
- Pharma policy with „radical transparency“
- Supervision and control

Response of the industry:

- Initiatives of self-regulation

Colombia: transparency in pharma sub-sector

- Decision making in regulatory processes
- Drug price regulation
- Comparison of drug prices
- Prescription and use of drugs
- „Sunshine Act“ a la Colombiana
- Self-regulation of Industry
- Transparency reform in Invima (FDA of Colombia)
- Médicos sin Marca Colombia



TERMÓMETRO DE PRECIOS DE MEDICAMENTOS REGULADOS



La Comisión Nacional de Precios de Medicamentos y Dispositivos Médicos -CNPMDM- ha establecido el precio máximo de venta a nivel mayorista para diferentes medicamentos que se comercializan en Colombia. Con esta herramienta puede consultar el precio máximo de venta a nivel mayorista de estos medicamentos en Colombia antes de la regulación de precios (Art. Reg) y después de la regulación (Actual), así como la comparación que la Comisión realizó sobre sus precios a nivel internacional para establecer el precio regulado. Los precios internacionales se encuentran en pesos colombianos (COP) y corresponden al periodo entre abril de 2012 a marzo de 2013 para las Circulares 04 y 05 de 2013 y octubre de 2012 a octubre de 2013 para las Circulares 07 de 2013 y 01 de 2014.

El precio para Colombia (Actual) corresponde al precio máximo de venta vigente para todas las operaciones comerciales a nivel mayorista en Colombia. Este valor incorpora el ajuste realizado mediante la Resolución 0718 de 2015 del Ministerio de Salud y Protección Social.

CONSULTE AQUÍ POR CADA MEDICAMENTO QUE SE ENCUENTRA REGULADO

Principio Activo	Nombre Comercial	Titular	Cantidad de Principio Activo	Unidades de Dispensación	Circular de Regulación	PRECIO MÁXIMO DE VENTA A NIVEL MAYORISTA EN COLOMBIA
GALANTAMINA	REMINYL	JANSSEN	8mg	7 CAPSULAS	Circular 04 de 2013	\$20.917 COP

País	Precio (COP)
ESPAÑA	\$9.265
FRANCIA	\$16.964
PORTUGAL	\$17.803
COLOMBIA (Actual)	\$20.917
REINO UNIDO	\$27.257
NORUEGA	\$29.595
BRASIL	\$31.961
AUSTRALIA	\$32.383
ESTADOS UNIDOS	\$36.779
CANADÁ	\$48.426
PERÚ	\$73.969
COLOMBIA (Ant. Reg)	\$113.297

En el siguiente enlace podrá conocer más sobre las políticas de regulación de la Comisión Nacional de Precios de Medicamentos y Dispositivos Médicos: <http://www.minsalud.gov.co/salud/MT/Paginas/medicamentos-regulacion-precios.aspx>



Consulta los precios que ofrecen los titulares de cada una de las marcas comerciales para un mismo principio activo. Podrás observar el precio equivalente por tableta de cada una de estas presentaciones, de modo que puedas comparar las distintas ofertas del mercado que existen para el mismo principio activo.

SELECCIONA EL MEDICAMENTO QUE DESEAS CONSULTAR

ESOMEPRAZOL 20 mg

Estas son las marcas que contienen ESOMEPRAZOL 20 mg Y el cálculo de sus precios por tableta



Los precios aquí presentados corresponden al precio promedio reportado por los laboratorios al Sistema de Información de Precios de Medicamentos - SIMED - en el 2014. No representa un precio máximo de venta establecido por el Gobierno Nacional.

ESOMEPRAZOL COLMED	\$960
SAK SIEGFRIED	\$1.079
ESOMEPRAZOL AMERICAN-GENERICS	\$1.353
ESOMEPRAZOL LA-SANTE	\$1.402
ESOMEPRAZOL TECNOQUIMICAS	\$1.600
ESODEX ADEXA	\$1.828
ESOMEPRAZOL GENFAR	\$2.110
GARMISCH ESOMAX GARMISCH	\$3.675
MELCONAR ANZO	\$3.714
ESOIN JOINPHARM	\$3.977
ESOMED NOVAMED	\$4.163
RUMONAL PRO LEGRAND	\$5.049
ESOTLEN METLEN-PHARMA	\$5.082
ESOPRAX LEGRAND	\$5.492
CRONOPEP BIOTOSCANA	\$6.183
NEXIUM MUPS ASTRAZENECA	\$6.644
NEDOX LAFRANCOL	\$6.666
ESOZ GALENO	\$8.767




Colombia: studies on transparency and corruption risks in the health sector

➤ Study of transparency initiatives in the pharma sector

- Led by committed public leaders
- Experimental, good initial results! Sustainability?
- Lack of clear objectives: monitoring for results?
- Intra-institutional coordination and anchoring = weak (no policy)
- Need to involve stakeholders in design and implementation
- Strengthen links of transparency, accountability, participation
- Need for intra-ministerial transparency lead close to Minister

➤ Study on risks and tolerance of corruption and risks of opacity in key processes of health sector

- Independent but coordinated with Ministry and Super-Salud
- All key actors involved in analysis and remedies
- Survey on experience, perceptions and tolerance gauging
- Analysis of macro-processes → priorities to select key processes and analyze them with risk-based methodology



Recomendaciones de Política:
En busca de una mayor integridad y transparencia en el sistema de salud colombiano

"Es posible vivir sin corrupción"

Supersalud UNIA GES UNIVERSIDAD DE ANTIIOQUIA FIAPP ACTA

Challenges for Colombia

- ▶ How to achieve continuity with a new government from a different political spectrum, with different priorities and political economy to satisfy?
- ▶ No clear alliance of societal actors who demand consistently for change (civil society, professional organizations, universities, etc.) – several of the transparency initiatives are in risk of being discontinued.
- ▶ Transparency and integrity commitments in the health sector are not integral part of international commitments (e.g. OGP, EITI, or others) and thus lack international “pressure” for reporting.
- ▶ End of donor support for transparency and anti-corruption initiatives in general and the health sector in particular coincides with change of government.
- ▶ How to build / strengthen bridges between health and governance communities (government, CSO, universities, donors)?
- ▶ Current role of universities (drugs; institutional transparency; policy impulse and risk-management; Médicos sin Marcas)

Information on Colombian health sector transparency and anti-corruption initiatives available in Spanish at

www.actuecolombia.net

Recap

- ▶ Different systems, different risks and system reforms harbour new risks for corruption
- ▶ Little documented evidence of how corruption, opacity and tolerance for corruption plays out in different countries and systems → particular lack of knowledge on policy, regulatory and institutional capture
- ▶ Little documented evidence of what works, what not, in which context, why.
- ▶ Need to translate main principles of good governance (transparency, access to information, accountability, participation, integrity) into coordinated and coherent action.
- ▶ Need to link anticorruption work with sector / institutional objectives → tangible, monitorable results with political gains.
- ▶ Important opportunities for donors to provide technical assistance in continuous-intermittent way
- ▶ Relevance of social pressure / demand (role for donors)



**Generation & access to info + accountability + participation
→ cultural change**



GRACIAS POR SU INTERES

Karen.hussmann@gmail.com